BioNTech SE will announce its financial results for the third quarter of 2026 on November 3, 2026, followed by a conference call and webcast for investors and the public. The company, known for its innovative cancer therapies and mRNA technology, will provide updates on its financial performance and corporate developments. This event is significant as it offers insights into BioNTech's progress in oncology and other serious diseases. The webcast and presentation will be accessible on BioNTech's website, with a replay available for 30 days after the call.
As of Oct 20, 2026 18:01 WIB, BioNTech SE's ADR (BNTX) is trading at USD 89.03 on Pluang, showing a slight decline of 0.20% in one day. The company holds a market capitalization of $22.41 billion and an enterprise value of $6.18 billion, reflecting its significant presence in the health sector. These figures provide a current snapshot of BioNTech's market standing ahead of its upcoming Q3 2026 financial results announcement on November 3, 2026.
BioNTech presented new Phase 2 clinical trial data at ESMO 2026 showing promising results for pumitamig, a PD-L1×VEGF-A bispecific immunomodulator, combined with chemotherapy in treating advanced cancers including metastatic non-small cell lung cance...
Moderna's stock dropped 10% following a strong rally driven by its personalized cancer vaccine progress. The decline is seen as profit taking ahead of a critical late-stage melanoma trial data release expected later this month. Moderna's oncology eff...
Moderna shares surged 6% amid a broader market rotation from AI and tech stocks into healthcare, outperforming peers BioNTech and Pfizer. This rally is supported by positive clinical data from August showing Moderna's personalized mRNA cancer vaccine...
